Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Júlia Tamáska"'
Autor:
Katalin Rajczy, Judit Várkonyi, Júlia Tamáska, Tamás Masszi, László Gopcsa, Péter Farkas, Ágnes Padányi
Publikováno v:
Open Medicine, Vol 4, Iss 4, Pp 501-505 (2009)
The authors report on two multiple myeloma sibling pairs. In the absence of a known disease-specific marker one can only speculate on an explanation: is it because of inherited errors or is it related to the same environmental exposure, or both? In t
Publikováno v:
Hungarian Medical Journal. 1:523-528
Background: Authors report on a patient with monoclonal gammopathy who was misdiagnosed as multiple myeloma and treated with alkylating agent, melphalan. The patient developed myelodysplasia and eventually died of disease complications. The coexisten
Autor:
Júlia Schönléber, András Matolcsy, Júlia Tamáska, Judit Várkonyi, Tamás Masszi, László Gopcsa, Gábor Tarkovács, Judit Jánosy, Ferenc Kolozsváry, Judit Csomor
Publikováno v:
Hungarian Medical Journal. 1:235-240
It has long been believed that the coexistence of myelo- and lymphopoietic malignancies may develop as treatment-related complications. However, there are reports on the coincidence of lymphoid and non-lymphoid haemopoietic disorders, unrelated to th
Autor:
Júlia Tamáska, Maria Kost-Alimova, George Klein, Gergely Kriván, György Fekete, Stefan Imreh, Gabor G. Kovacs, Irén Haltrich
Publikováno v:
Cancer Genetics and Cytogenetics. 164:74-80
The virtually obligatory presence of the Philadelphia chromosome may suggest a causal homogeneity, but chronic myelogenous leukemia (CML) is a clinically heterogeneous disease. This may be a consequence of the variable BCR breakpoints on chromosome 2
Autor:
Júlia Tamáska, Katalin Pálóczi, László Gopcsa, András Matolcsy, Katalin Jakab, Éva Rajnavölgyi, Luca Kormos, Péter Gogolák, Aniko Banyai
Publikováno v:
European Journal of Haematology. 75:346-351
Objectives Accumulating evidence suggests that non-T, non-B cell CD4+CD56+ neoplasms with lymphoblastic morphology include clinically and immunophenotypically diverse entities. Although their cells of origin or classification are still controversial
Autor:
Zoltán Mátrai, Andrea Sipos, Attila Tordai, Sandor Lueff, Gabriella Halm, Anikó Szilvási, Tamas Masszi, Viktória Király, Gabor Mikala, Zoltán Csukly, Sarolta Nahajevszky, Júlia Tamáska, Nóra Meggyesi, Hajnalka Andrikovics, Nóra Lovas
Publikováno v:
Orvosi hetilap. 148(5)
The Val617Phe point mutation of Janus kinase 2 gene is believed to participate in the pathogenesis of myeloproliferative syndrome characterised by the clonal alteration of hematopoetic stem cells. According to current results, the frequency of Val617
Autor:
Laszlo Bereczki, Hajnalka Andrikovics, Eniko Bagdi, László Gopcsa, Attila Tordai, Júlia Tamáska, László Krenács, Gabriella Halm, András Kozma, Emma Ádám
Publikováno v:
Virchows Archiv : an international journal of pathology. 449(4)
Hepatosplenic T-cell lymphoma is a rare, clinically aggressive lymphoma. Most cases represent a neoplasm of mature non-activated gammadelta T cells. Isochromosome 7q i(7)(q10) is thought to be the primary cytogenetic abnormality of this disease. In t
Autor:
Esther Zipperer, Natalie A. Twine, Matthew Arno, Ghulam J. Mufti, Guillermo Sanz, Norbert Gattermann, Joop Gaken, Azim M Mohamedali, Nigel Westwood, Petar Antunovic, Ulrich Germing, Zaida García-Casado, A.A.N. Giagounidis, Szabolcs Benedek, José Cervera, Bruno Cassinat, J J Kiladjian, W Ingram, B. Czepulkowski, Júlia Tamáska, J Csomer, Judit Várkonyi, T. Kontou, Pierre Fenaux, Nicholas Lea
Publikováno v:
Leukemia
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a31da331b70bfa5c68aa7404cd8be7a8
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16033
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=16033
Autor:
Irén, Haltrich, Maria, Kost-Alimova, Gábor, Kovács, Gergely, Kriván, Júlia, Tamáska, George, Klein, György, Fekete, Stefan, Imreh
Publikováno v:
Cancer genetics and cytogenetics. 164(1)
The virtually obligatory presence of the Philadelphia chromosome may suggest a causal homogeneity, but chronic myelogenous leukemia (CML) is a clinically heterogeneous disease. This may be a consequence of the variable BCR breakpoints on chromosome 2
Autor:
Sarolta, Nahajevszky, Balázs, Kapás, Emma, Adám, Nóra, Lovas, Gabriella, Halm, László, Gopcsa, Júlia, Tamáska, Anna, Poros
Publikováno v:
Orvosi hetilap. 145(4)
Treatment outcome in patients with acute myeloid leukemia are determined by prognostic factors.Between January 1996 and December 2001 160 patients were treated with newly diagnosed acute myeloid leukemia. Treatment results were analysed according to